mountainman
Well-Known Member
- Messages
- 45
- Type of diabetes
- HCP
- Treatment type
- I do not have diabetes
As I said in my earlier post, I do hope Afrezza comes over here and it looks promising. I think there is a lot of paranoia out there these days about pharmaceutical financial gain. We will have to wait for NICE to make their findings, hope it's passed soon. I wonder if it will be available on prescription, this or next year.
Wow, a lot of pessimism on this thread. Maybe that's what happens when you've had T1 for a long time and have been disappointed by "breakthroughs" in the past. However, I am still keen to try to this and hope it makes its way on to the NHS soon. For those asking about "real life" experiences by "real people" you only need to search Twitter to see literally hundreds of remarkable, real-life, non-endorsed experiences. The verdict is out, and it is extremely positive so far.
Not so much pessimism as a huge dose of reality. The last "amazing" inhaled insulin was withdrawn from the market after two years following the determination that it caused lung cancer.Wow, a lot of pessimism on this thread. Maybe that's what happens when you've had T1 for a long time and have been disappointed by "breakthroughs" in the past. However, I am still keen to try to this and hope it makes its way on to the NHS soon. For those asking about "real life" experiences by "real people" you only need to search Twitter to see literally hundreds of remarkable, real-life, non-endorsed experiences. The verdict is out, and it is extremely positive so far.
I've not had time to read all of this thread but commented on this story on another thread a month or two back. From memory, the American health body (can't remember the initials!) approved it's use but strictly on the condition that there were significant trials carried out to determine the effect it has on the lungs and that the UK was stepping back until such time.
Definitely a 50/50 case of optimism vs pessimism for me.
I think it actually says on the Afrezza website that it (from memory) 'may damage lungs'. For me, if that was minor and that was the only problem with it, I would still bite the hand off them to get it.
I really hope it's as good as reports suggest.
Having seen how badly COPD and asbestosis affects people there is no way I would have anything that could damage lungs. No way. No matter if it did ease injections etc.having been on insulin for 30 years and no complications why would I want to risk my breathing. How can any damage to lungs be minor even whether it is a minority of people or minor damage?
If you damage lungs then that is not good.
The social enigma of syringes if one thing, agreed, but how Afrezza acts in a person's system in BY FAR the biggest part of this medication. Forget everything you know about insulin and start all over, because Afrezza is NOT LIKE ANYTHING ELSE ON THE MARKET. Can you imagine not having to do intense carb counting ?( although some would be smart ) . Can you imagine not having to concern your self with hypoglycemia ? Afrezza is REAL TIME INSULIN - acts as the pancreas does, no need to eat again in 3 hours after taking your injection. Little to no worries about going into a low, less to no weight gain as there is no need to eat again as with injectables since they are in your system for 5 hours, while Afrezza has done its work and is gone in 2 1/2 hours. With Afrezza if a person has a continuous glucose monitor and becomes aware they are going high, 4 U Afrezza can have it under control in a half hour.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm
Here's what I read some time ago.
@mountainman
I do think the quote above stinks of a sales pitch and, more seriously, a lack of knowledge and understanding of diabetes. Period (as they say in the USA).
The bottom line for me is that this drug is purely a faster acting fast acting insulin.
What any T1 diabetic will tell you is quite simple. We cannot produce insulin thus we inject it. We need to know how the food we are eating effects our BG levels. We need to know how much insulin is required to counteract this. We need to know when to take the insulin to have the maximum effect.
All the sales pitches in the world will not change the facts above and they are grossly over-simplified.
Yes, the product sounds great. Will it change my daily life as a T1 diabetic? I don’t think so. If I eat a carb heavy meal I can’t just say, ok 4U inhaled, sorted. I’d hypo 20mins later. I would need to wait until the delayed spike was due and then take it. Yes, over time you would learn but your comments are far too simplistic and frankly dangerous regarding hypos.
“A Review of Inhaled Technosphere Insulin”, Neumiller, Campbell & Wood found a greater incidence of hypoglycaemia in the trials of T2 diabetics using Technosphere compared to regular brand fast acting insulin. Not just in the initial 6 months, it increased in time over a four year study.
What people who don’t live in the diabetic world can’t understand is the complexity of the condition and how many factors come into play. This is not replicating the pancreas. If you want to make that claim then you need a product which can be in the system and kick in when BG level rises just as the pancreas does. There is one in production if you look for it.
I said earlier I had 50% optimism for this product, I think there could be great benefits for something which acts so quickly, I really do. However, I think your comments are seriously flawed.
http://www.fiercepharma.com/press-r...afrezza-only-inhaled-insulin-now-available-In
In addition to low blood sugar (hypoglycemia), other possible side effects associated with Afrezza include cough, throat pain or irritation, headache, diarrhea, tiredness, and nausea
http://www.drugs.com/pro/afrezza.html
Decline in Pulmonary Function
Afrezza causes a decline in lung function over time as measured by FEV1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, Afrezza-treated patients experienced a small [40 mL (95% CI: -80, -1)] but greater FEV1 decline than comparator-treated patients. The FEV1 decline was noted within the first 3 months, and persisted for the entire duration of therapy (up to 2 years of observation). In this population, the annual rate of FEV1decline did not appear to worsen with increased duration of use. The effects of Afrezza on pulmonary function for treatment duration longer than 2 years has not been established. There are insufficient data in long term studies to draw conclusions regarding reversal of the effect on FEV1after discontinuation of Afrezza. The observed changes in FEV1 were similar in patients with type 1 and type 2 diabetes.
Assess pulmonary function (e.g., spirometry) at baseline, after the first 6 months of therapy, and annually thereafter, even in the absence of pulmonary symptoms. In patients who have a decline of ≥ 20% in FEV1 from baseline, consider discontinuing Afrezza. Consider more frequent monitoring of pulmonary function in patients with pulmonary symptoms such as wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue Afrezza. [see Adverse Reactions
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?